ivermectin extended release (LYN‐063) / Lyndra - LARVOL DELTA

Arturo LoAIza-Bonilla, MD MSEd @DrBonillaOnc Ivermectin and anti-parasitic drugs DO NOT cure cancer.

An Open-label, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of LYN-163 in Healthy Volunteers (ANZCTR) - P1 | N=25 | Completed | Sponsor: Lyndra®Therapeutics, Inc. (Lyndra) | Recruiting ➔ Completed

Trial completion • Infectious Disease • Malaria

Pharmacokinetics of extended-release ivermectin microspheres after oral administration to healthy pigs. (PubMed, J Vet Pharmacol Ther) - "Moreover, the AUC of the microcapsule groups was increased from 1,129.76 ± 245.62 to 1,607.33 ± 343.35 hr ng/ml compared with the premix groups, and the relative bioavailability increased by an average of 17.53% after oral administration with ivermectin microspheres. Multiple-dose administration also indicated pigs fed with ivermectin microspheres can get a higher minimum steady-state concentration and a longer maintenance time than ivermectin premix."

Clinical • Journal • PK/PD data